Entropy Neurodynamics Limited (ASX:ENP)

Australia · Delayed Price · Currency is AUD

0.0410

-0.0010 (-2.38%)

Sep 10, 2026, 4:10 PM AEST

Market Cap	66.94M +50.0%
Revenue (ttm)	1.91M +20.5%
Net Income	-4.87M
EPS	-0.00
Shares Out	1.63B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	430,990
Open	0.0420
Previous Close	0.0420
Day's Range	0.0400 - 0.0420
52-Week Range	0.0250 - 0.0460
Beta	-0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Entropy Neurodynamics

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol ENP

Full Company Profile

Financial Performance

In fiscal year 2026, Entropy Neurodynamics's revenue was 1.91 million, an increase of 20.53% compared to the previous year's 1.58 million. Losses were -4.87 million, -8.69% less than in 2025.

Financial Statements